Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

被引：0
|
作者：
Jumpei Teramachi
Hirokazu Miki
Shingen Nakamura
Masahiro Hiasa
Takeshi Harada
Masahiro Abe
机构：
[1] Tokushima University Graduate School of Biomedical Sciences,Department of Hematology, Endocrinology and Metabolism
[2] Okayama University Graduate School,Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
[3] Tokushima University Hospital,Division of Transfusion Medicine and Cell Therapy
[4] Tokushima University Graduate School of Biomedical Sciences,Department of Community Medicine and Medical Science
[5] Tokushima University Graduate School of Biomedical Sciences,Department of Orthodontics and Dentofacial Orthopedics
来源：
Journal of Bone and Mineral Metabolism | 2023年 / 41卷
关键词：
Myeloma bone disease; Receptor activator of nuclear factor-κB ligand; Bone-modifying agents; Proteasome inhibitors; Daratumumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：388 / 403
页数：15
相关论文
共 50 条
  • [41] Gene expression profiling in multiple myeloma cells treated with the novel anti-myeloma agents zoledronate and fluvastatin.
    Molloy, TJ
    Cindy, BB
    Deng, YM
    Spencer, A
    Ma, DF
    BLOOD, 2005, 106 (11) : 351B - 351B
  • [42] Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy
    Valkovic, Toni
    Nacinovic, Antica Duletic
    Petranovic, Duska
    MEDICAL HYPOTHESES, 2013, 81 (06) : 1137 - 1140
  • [43] Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Valent, Jason
    Garcia, Alex V. Mejia
    Faiman, Beth M.
    Khouri, Jack
    Samaras, Christy J.
    Anwer, Faiz
    Khorana, Alok A.
    BLOOD CANCER JOURNAL, 2021, 11 (06)
  • [44] Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
    Rajshekhar Chakraborty
    Lisa Rybicki
    Jason Valent
    Alex V. Mejia Garcia
    Beth M. Faiman
    Jack Khouri
    Christy J. Samaras
    Faiz Anwer
    Alok A. Khorana
    Blood Cancer Journal, 11
  • [45] Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries
    Pessoa de Magalhaes Fillio, Roberto Jose
    Crusoe, Edvan
    Riva, Eloisa
    Bujan, Willen
    Conte, Guilhermo
    Navarro Cabrera, Juan Ramon
    Katerine Garcia, Diana
    Quintero Vega, Guilhermo
    Macias, Jose
    Oliveros Alvear, Jose Willian
    Royg, Mercedes
    Andino Neves, Lidiane
    Lopez Dopico, Jose Luis
    Espino, German
    Rosales Ortiz, Douglas
    Socarra, Zurelis
    Fantl, Dorotea
    Ruiz-Arguelles, Guillermo J.
    Maiolino, Angelo
    de Moraes Hungria, Vania Tietsche
    Harousseau, Jean-Luc
    Durie, Brian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01): : E43 - E50
  • [46] Myeloma bone disease: Pathogenesis and treatment - From the multiple myeloma research foundation
    Anderson, KC
    Roodman, GD
    ONCOLOGY-NEW YORK, 2005, 19 (08): : 983 - +
  • [47] Anti-myeloma properties and mechanism of polymethyl methacrylate bone cement and allograft bone in vitro
    Yao, Xing-Chen
    Wei, Yan-Zhe
    Luo, Hui
    Du, Xin-Ru
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (01): : 1276 - 1281
  • [48] Management of bone disease in multiple myeloma
    Terpos, Evangelos
    Berenson, James
    Raje, Noopur
    Roodman, G. David
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (01) : 113 - 125
  • [49] Myeloma bone disease: pathophysiology and management
    Terpos, E
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1223 - 1231
  • [50] Advances in the management of myeloma bone disease
    Shipman, CM
    Oyajobi, BO
    Mundy, GR
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (16) : 2781 - 2791
12345